GIOVANNONI ROBERTO

Ruolo: 
ricercatore
Settore scientifico disciplinare: 
PATOLOGIA GENERALE (MED/04)
Telefono: 
0264488231
0264488340
Stanza: 
U8, Piano: IV, Stanza: 4008
Via Cadore, 48 - 20900 MONZA
U8, Piano: IV, Stanza: L. 4.7
Via Cadore, 48 - 20900 MONZA
Orario di ricevimento: 

Biografia

Academic and research appointments:

2001-2002, Post-graduate fellowship at the Stem Cell Research Institute (SCRI) – Dibit Ospedale San Raffaele

2002-2003, Post-graduate fellowship at the Department of Experimental Medicine & Biotechnology, UNIMIB

2002-2004, Principal Investigator of Telethon Project #GSP010316 “Pathogenesis of polyglutamine disorders: Transgenic models”

2003-2004, Fellowship at the Department Experimental Medicine & Biotechnology, University of Milano-Bicocca

2004 to date, Research Staff Scientist at the Molecular Medicine Laboratory – Dept. Surgical Sciences, University of Milano-Bicocca

2004 to date, Participating Scientist at the PhD Program in Translational and Molecular Medicine – University of Milano-Bicocca

2004 to date, Assistant Professor of Pathology & Immunology at School of Medicine – University of Milano-Bicocca

2005 to date, Head of Laboratory of Experimental Models at the School of Medicine and Surgery, University of Milano-Bicocca

2005-2008, Professor of “Genetic Engineering in Experimental Models” at School of Medicine – University of Milano-Bicocca

2006, External referee at the Thesis Commission of the Programa de Doctorat: Antropologia Biològica, Universitat de Barcelona.

2008-2011, Professor of “In Vivo Techniques” at School of Medicine – University of Milano-Bicocca

2010-2013, Co-owner and consultant at BiOnSil srl, spin-off of the University of Milano-Bicocca

2011-to date, Professor of “Molecular Mechanisms of Diseases” at School of Medicine – University of Milano-Bicocca

2014 to date, Appointed Scientific Member of the Local Committee for Animal Welfare according to European Directive 2010/63/UE and Italian D.Lgs. 26/2014 on the protection of animals used for scientific purposes

2014-2016, Co-promoter of the PhD research program for Dr. Marco De Giorgi, Medical University of Gdansk, Poland

2015 to date, Co-promoter of the PhD research program for Dr. Matteo Riva, KU Leuven, Belgium

2015 to date, Co-founder of GRG Gene Technology SA.

2016 to date, Co-founder of Educational Factory s.r.l.

Areas of Interest: Molecular and Translational Medicine; Cardiovascular Biologuy and Medicine; In vivo experimental models development; Cancer Biology and Therapy; Inflammation

Scientific Interests: Dr. Giovannoni has focused his research activity mainly on the production and characterization of experimental in vivo models for human diseases. The investigation of pathogenesis of human diseases in experimental models has been carried out in the following collaborative research projects:

-Study of molecular and diagnostic markers in cancer biology and cancer drug resistance (Lupia et al., Stem Cell Rep, 2018; Caria et al., J Cancer, 2017; Giovannoni et al, Hepatology, 2016; Romano et al, Oncotarget, 2016; Grassilli et al, Oncogene, 2016; Conconi et alTumor Biol, 2016; Salerno et alBiophys J, 2016; Agostini et al, Cancer Biol Ther, 2015; Grassilli et al, PLoS ONE, 2014; Grassilli et al, Clin Cancer Res, 2013; Tempestini et alNucleic Acids Res, 2013)

- Study of adenosine and extracellular nucleotide metabolism in the molecular mechanisms of cytoprotection against inflammatory stimuli (Chisci et al., Free Rad Biol Med, 2017; De Giorgi et al., Plasmid, 2015; Cinti et al., PLoS ONE, 2015; De Giorgi M et al., Nucleosides Nucleotides Nucleic Acids, 2014);

-Study of the effects of the systemic and local inflammation induced by hypercholesterolemic diet in pre-clinical models of atherosclerosis (Giovannoni et al, Patent pending, 2016; Busnelli et al.PLoS ONE, 2013; Busnelli et al.Atherosclerosis, 2009)

-Study of the role of nitric oxide and heme oxygenase-1 in the prevention of intimal hyperplasia development in an in vivo model and in vitro on vascular smooth muscle cells (Cerrito et al., Biol Pharm Bull, 2011; Scagliarini et al.Basic Clin Pharm Toxicol, 2008)

-Production of hCD55-transgenic pigs for xenotransplantation studies (Lavitrano et al., Methods Mol Biol; 2013; Bacci et al., Theriogenology, 2009; Smolenski et al., Cardiovasc Res, 2007; Lavitrano et al., Reprod Fertil Dev, 2006; Lavitrano et al., PNAS, 2002)

-Production of pre-clinical animal models for the study of ischemia-reperfusion injury (Andria et al., PLoS ONE, 2013; Lavitrano et al., FASEB J, 2004)

-Production of multi-gene transgenic pigs for xenotransplantation studies (Cinti et al., PLoS ONE, 2015; De Giorgi et al., Plasmid, 2015; De Giorgi et al., Nucleosides Nucleotides Nucleic Acids, 2014; Vargiolu et al., Transpl Proc, 2010; Webster et al., Mol Reprod Dev, 2005)

-Vectors for transgenesis: a) use of non-viral episomal vectors to genetically modify animals (Manzini et al., PNAS, 2006); b) use of adeno-associated vectors for retino-specific gene therapy in pre-clnical animal models (Mussolino et al., Gene Ther, 2011)

-Study of hereditary (neuromuscular, neurodegenerative or channellopathies) disorders in in vitro and in vivo models (Binda et al., Front Cell Neurosci, 2018; Bugiardini et al., Neuromusc Disord, 2015; Giovannoni et al., Neuron Glia Biology, 2007; Canzoniere et al, J Neurosci, 2004)

Patents:

Giovannoni R, Romano G, Fogher N, Giuffré MR, Pettinato M, Reggi S (2016) Compositions for the administration of ApoA1 and dosages. Patent pending No. 102016000081193, PCT/IB2017/054646.

- Cerrito MG, Giovannoni R, Grassilli E, Lavitrano M, Masiero L, Pisano F, et al. (2014) COMBINATIONS OF A BTK INHIBITOR AND FLUOROURACIL FOR TREATING CANCERS. Patent No. PCT/EP2014/066724, WO2015/015013.

- Cerrito MG, Giovannoni R, Grassilli E, Lavitrano M, Masiero L, Pisano F, et al. (2013) PHARMACEUTICAL KIT FOR USE IN THE TREATMENT OF COLON AND COLORECTAL CANCER. Patent No. EP 2 832 358 A1.

Pubblicazioni

  • Lupia, M., Angiolini, F., Bertalot, G., Freddi, S., Sachsenmeier, K., Chisci, E., et al. (2018). CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. STEM CELL REPORTS, 10. Dettaglio
  • Chisci, E., De Giorgi, M., Zanfrini, E., Testasecca, A., Brambilla, E., Cinti, A., et al. (2017). Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro. FREE RADICAL BIOLOGY & MEDICINE, 108, 320-333. Dettaglio
  • Cilibrasi, C., Riva, G., Romano, G., Cadamuro, M., Bazzoni, R., Butta, V., et al. (2017). Resveratrol impairs glioma stem cells proliferation and motility by modulating the wnt signaling pathway. PLOS ONE, 12(1). Dettaglio
  • Grassilli, E., Pisano, F., Cialdella, A., Bonomo, S., Missaglia, C., Cerrito, M.G., et al. (2016). A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. ONCOGENE, 35(33), 4368-4378. Dettaglio
  • Giovannoni, R., & Villanueva, A. (2015). Circulating tumor cells and cholangiocarcinoma. HEPATOLOGY, 63(1), 23-25. Dettaglio